OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Discovery Today is 58. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	293
Contents page	257
CIPDB: A biological structure databank for studying cation and π interactions	196
The potential value of 5-androstenediol in countering acute radiation syndrome	163
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	146
The recent progress of deep-learning-based in silico prediction of drug combination	146
Antibody–drug conjugates: What drives their progress?	142
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	141
Models and approaches to comprehend and address glial inflammation following spinal cord injury	133
Tubulin targeting agents and their implications in non-cancer disease management	124
Accelerating the orphan GPCR pipeline: GPR149 as a case study in dual-domain target validation	108
Artificial-intelligence-guided autophagy modulation and nanomedicine design for precision photodynamic cancer therapy	108
The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	107
On-body drug delivery systems: State-of-the-art technologies, clinical application, and future perspectives	106
General aspects of powder rheology applied to pharmaceutical formulations	105
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	102
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	99
Next-generation lung-cancer-on-a-chip: Toward personalized therapy, AI, and CRISPR-driven models	98
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	97
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	95
Gastroretentive drug delivery systems: A holy grail in oral delivery	90
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	84
Computational modeling approaches and regulatory pathways for drug combinations	83
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	82
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	82

Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	79
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	79
Bridging data and drug development: Machine learning approaches for next-generation ADMET prediction	79
MRI assessment of cerebral perfusion in clinical trials	78
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States	77
Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?	75
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	75
Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection	74
The evolution of ethical and legal regulations of drug research	73
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development	73
Engineering virus-like particles for lymph-node targeted cancer immunotherapy: strategies, challenges, and future prospects	73
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein	72
Gaps between medical biology and AI drug discovery	72
Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis	69
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases	69
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy	68
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio	68
Global landscape and translational trajectories of flavonoid-based wound-healing research	67
Recent advances towards overcoming the blood–brain barrier	66
Estimating the global inventory of deprioritized clinical-stage drug development programs: Toward a market for shelved assets	65
Steps toward nebulization in-use studies to understand the stability of new biological entities	65
Caught between a ROCK and a hard place: current challenges in structure-based drug design	65
A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs	64
Advancing pharmacogenetics research in Africa: the “Project Africa GRADIENT” initiative	63
Pathogenic TDP-43 in amyotrophic lateral sclerosis	61
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	61
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?	61
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases	61
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance	59
Regulatory approvals of therapeutic biologics: continuing progress or plateauing out compared with those of small molecules?	59
The emerging role of fatty acid binding protein 7 (FABP7) in cancers	58
Targeted protein degradation: current molecular targets, localization, and strategies	58
Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer	58